Jeffrey Zen-Ji Rico, MD
Endocrinology, Diabetes & Metabolism · Morgantown, WVNPI 1255788873
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 32.0% of the total. Reporting peaked in 2023 at $464 and has fallen 54.8% since, to $210 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in WV, where the typical reported total is $1,166.
Across 69 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$368
- Medtronic$169
- Xeris Pharmaceuticals, Inc.$85
- Lilly USA, LLC$85
- Cequr Corporation$72
- Insulet Corporation$68
- plus $303 from 14 others
What the payments were for
- Food & beverage$1,149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $368 |
| Medtronic | 8 | $169 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Lilly USA, LLC | 5 | $85 |
| Cequr Corporation | 2 | $72 |
| Insulet Corporation | 3 | $68 |
| Dexcom, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| Novartis | 1 | $24 |
| Chiesi USA, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Amgen | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$1,149 in reported general payments places this provider in the 45th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $110,785 |
| JardianceEmpagliflozin | 89 | $88,611 |
| TrulicityDulaglutide | 53 | $60,057 |
| MounjaroTirzepatide | 25 | $26,061 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $16,337 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $12,410 |
| Novolog FlexpenInsulin Aspart | 41 | $10,870 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $8,771 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $6,897 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 38 | $4,736 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,043 |
| SynthroidLevothyroxine Sodium | 20 | $1,798 |
| Testosterone Cypionate | 36 | $1,504 |
| Hydrocortisone | 29 | $1,421 |
| Levothyroxine Sodium | 165 | $1,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $368 | $110,78596 claims |
| Boehringer IngelheimJardiance | $38 | $88,61189 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $85 | $86,11878 claims |
| AbbVieSynthroid | $14 | $1,79820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Morgantown
- Jessica PeriniMorgantown$10K
- Jennifer TurnerMorgantown$6K
- Adnan HaiderMorgantown$3K
- Jennifer GiordanoMorgantown$2K
- Nadia BarghouthiMorgantown$1K
- Apoorva IyerMorgantown$1K
- Tariq LatifMorgantown$844
- Mehjabeen SadiqMorgantown$684
- Sarah FatimaMorgantown$292
- Ann-Marie BusickMorgantown$227
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.